individual is contributing towards the trials; perhaps this could be detailed in the contributions sections? They must meet ICMJE author criteria.
Intro: 1. "the scars resulting from these chest incisions are always disfiguring.
[3]" -I suggest the authors tone down this statement to "...may keloid and therefore, be aesthetically undesirable or symptomatic". 2. "and different suture times may have produced the outcome. [7] " -I think you mean "and different suture times may have confounded the outcome"? In general the introduction good, but rather long and may benefit from truncation.
Methods:
This should be written in accordance with the CONSORT statement, with sections in the order prescribed as at present, the order is dysjointed. 1. The outcome measures are insufficiently described. The primary outcome should be singular; at present there are several outcomes which contribute to the stated primary outcome of "...the aesthetic appearance of the scar over the 3-month follow-up period, including the width of the scar for both halves and the scores on the Vancouver scar scale (VSS), patient and observer scar assessment scale (POSAS) and Visual analogue scale". I suggest that this is consolidated to one single measure eg. the overall POSAS score, given it's superiorty. It cannot/should not be a composite of several outcome measures. All other outcome measures can be of secondary interest and equally, must be justified. If you have a good measure of scars (POSAS) then why do you need VSS? or a VAS? This may be judged as unsuitable by the ethical panel as you're collecting unecessary extra patient-reported outcomes... If you do need multiple measures, this must be justified. 2. "single-centre, prospective, randomized controlled trial" All trials are prospective by definition, so there is no need to say prospective. 3. The inclusion criteria need elaboration -is this research on adults or children? What age group? What population? How will they be identified? Who will recruit patients? And will you include anyone having costal cartilage harvested for any operation (ears, noses, etc) or just your microtia population? 4. The exclusion criteria are inadequately described. What chronic diseases are important to exclude and why? How will you identify patients with 3mm thick skin preoperatively ie. when you recruit them as this will surely be an intraoperative finding? So, will you exclude them latently or keep them and analyse on an ITT basis? 4. I feel the authors should rethink their split-scar (within subject) randomisation -there is a wealth of data on this topic and its limitations in the absence of a cross-over or repeated measures design. The split-scar model may cause serious issues: a) There will be difficulty in assessing and interpreting outcomes (ie. which bit of the half of the scar does the patient/assessor look at to decide the outcomes? The middle of the half? The edge? The junction? All of it? Does the VSS/POSAS allow this approach i.e is it validated in a split-scar model? What if your new suture reduces tension on the other half of the incision, confounding the effect of the BID? Also, these are small incisions and is it practical to halve the wound for different suturing? And both halves will received a running intradermal (final, to approximate epidermis) suture so there will be a common factor, making the groups related rather than different...Moreover, a split-scar model would cause major issues with the statistical analysis and external validity; the observations would no longer be independent (as they're from the same wound, same person, etc) and so more complex modeling is required to adjust for this related data, meaning the sample must be much larger if you're seeking to find a prescirbed difference (certainly far more than the 20 planned). Overall, I think the authors should consider randomising patients, rather than using a split-scar model and tackle this first in a feasibility trial. 5. The exact statistical test used to analyse the data will depend on the type, releatedness and distribution of the data, which in turn depends on the outcome measure that you use. There's no need to stipulate this in such detail yet or the software used. 6. The authors must discuss if patients will be blinded and how. This would then imply whether outcome measures were blind. 7. The authors should record if/when skin is excised as clearly, when more skin is removed there will be more tension at the repair. This varaible could inform sensitivity analyses. 8. Scars take months-years to mature and a 3-month follow-up alone will not identify hypertrophic or keloid scars. Also, as scars mature, the PSOAS/VSS scores will change. The authors cite Quinn et al's work to justify their approach but Quinn's trial considered 77 traumatic lacerations closed with glue vs sutures and the agreement between 3 month and 1 year POSAS scar scores was not good (kappa=0.7; 95% CI 0.5 -0.9 which implies moderate agreement, with a confidence interval from no agreement to 0.9, strong). Quinn's data is not transferable to this trial and doesn't imply 3-monthyl followup is sufficient. I recommend the authors better justify theic choice of 3 month only follow-up (provide better date) or consider extending their surveillance period to capture all adverse outcomes (which is expected in trials these-days). 9. In the blinding paragraph there is a typo for POSAS. 10. How will the wounds be dressed afterwards? Will sticky strips (suture strips, steri-strips, etc) be applied? What will be post-op wound care regime entail? 11. Who will deliver/facilitate the outcomes measures? Will the authors be there or will an independent professional administer the questionnaires? Analysis: 1. Your sample size calculation is based on a "paired t-test" although this may need to change if you move to a between-subject design. Also, why was a difference of 5 points chosen? Is this a known minimally clinically important difference? This should be justified: I imagine this data is based on between subject measurements and so this may not be valid in a split-scar model. Also, a SD of 7 needs explaining. If this were designed as a feasibility RCT as I suggest, then a fixed sample size of 20 is acceptable (Lancaster et al. Design and analysis of pilot studies: recommendations for good practice. Journal of evaluation in clinical practice. 2004), but this is not based in statistical power. The trial should be registered on a trial database which I advise the authors to begin (eg. clinicaltrials.gov).
It is crucial that plastic surgeons undertake more trials and so I congratulate you all on your plans and design thus far. I sincerely hope that my comments are helpful to you in revising this manuscript, such that it is then acceptable for publication and I wish you the very best in doing so. I'd be happy to review a revision and provide any further explanations/information as needed.
VERSION 1 -AUTHOR RESPONSE
The article is very valuable. The design of the study is appropriate. The abstract section is very large it is better to modified. Unfortunately, I did not found result section in submission. Answer: Thank you for taking the time to review our manuscript. We have modified the 'Abstract' section in the revised manuscript. According to the Instructions for Authors, study protocols do not contain a Results section. The results will be published in peer-reviewed journals and presented at national and international scientific conferences after this trial is completed.
Replies to Reviewer #2: Reviewer #2: Trial possible in a defined population. Results will be of interest in wider population. Photographs and diagrams will be useful in the final report. Answer: Thank you for taking the time to review our manuscript. We sincerely appreciate your positive comments that affirm the significance of the trial. In addition, we will try our best to complete it.
Replies to Reviewer #3: Reviewer #3: Thank you for the opportunity to review your manuscript. This is a well-conceived trial with a clearl clinical need. I have several comments on how the protocol might be improved and hope that you find my comments contructive. Overall: I think this study protocol should be re-framed as a feasibility trial. The authors seek to try a new suturing technique but the only prior data is based upon case reports with little/no other observation data. I suggest the authors scope out the best design and outcomes in a feasibility trial; this allows for subsequent better designed pilot and then full (perhaps multicentre) trials. Ideally the title would mention the body site (chest) and structure (skin) concerned as at present, the title doesn't convey much about the trial. Alternatively the title could be simplified to "different suturing techniques" or something alike as it's rather long and complex at present. There are several authors, although I'm not clear what each individual is contributing towards the trials; perhaps this could be detailed in the contributions sections? They must meet ICMJE author criteria. Answer: Thank you very much for your helpful advice. We have reframed the study protocol as a feasibility trial according to your comments. In the revised manuscript, we have changed the title to "Different suturing techniques in thoracic incision: protocol for a feasibility randomised controlled trial". We have detailed each author's contribution in the Contributions section. (page 7) Intro: 1. "the scars resulting from these chest incisions are always disfiguring.
[3]" -I suggest the authors tone down this statement to "...may keloid and therefore, be aesthetically undesirable or symptomatic". Answer: Thank you for the suggestion. We have amended the "the scars resulting from these chest incisions are always disfiguring" to "the scars resulting from these chest incisions may become keloid and therefore be aesthetically undesirable or symptomatic" in the revised manuscript. 2. "and different suture times may have produced the outcome.
[7]" -I think you mean "and different suture times may have confounded the outcome"? In general the introduction good, but rather long and may benefit from truncation. Answer: Thank you for indicating the inappropriate word choice in our original manuscript. We have deleted some sentences in the revised version and made the Introduction section more concise. (page 2)
Methods: This should be written in accordance with the CONSORT statement, with sections in the order prescribed as at present, the order is dysjointed. Answer: Thank you very much for your helpful suggestions. We have reorganised the "Methods" section in accordance with the CONSORT statement. (page 2~7) 1. The outcome measures are insufficiently described. The primary outcome should be singular; at present there are several outcomes which contribute to the stated primary outcome of "...the aesthetic appearance of the scar over the 3-month follow-up period, including the width of the scar for both halves and the scores on the Vancouver scar scale (VSS), patient and observer scar assessment scale (POSAS) and Visual analogue scale". I suggest that this is consolidated to one single measure eg. the overall POSAS score, given it's superiorty. It cannot/should not be a composite of several outcome measures. All other outcome measures can be of secondary interest and equally, must be justified. If you have a good measure of scars (POSAS) then why do you need VSS? or a VAS? This may be judged as unsuitable by the ethical panel as you're collecting unecessary extra patientreported outcomes... If you do need multiple measures, this must be justified. Answer: The reviewer has suggested a very good point here. We also very much agree with your opinion. In the revised manuscript, we have reframed the study as a feasibility trial; thus, the outcome measures include feasibility and clinical outcome measures. In addition, feasibility is the primary outcome in this trial. By examining the potential of the scar assessment tools (POSAS, VSS, VAS, etc.), we will select an appropriate primary clinical outcome measure to inform the sample size for a future full RCT. 2. "single-centre, prospective, randomized controlled trial" All trials are prospective by definition, so there is no need to say prospective. Answer: Thank you for indicating the inappropriate word choice in our original manuscript. We have deleted the word "prospective" in the revised version. 3. The inclusion criteria need elaboration -is this research on adults or children? What age group? What population? How will they be identified? Who will recruit patients? And will you include anyone having costal cartilage harvested for any operation (ears, noses, etc) or just your microtia population? Answer: Thank you very much for the suggestions. This research will be focused on young people aged 6~18 years old. In addition, the clinicians will recruit participants during their hospitalisation. Patients who undergo costal cartilage harvesting for microtia repair will be included. 4. The exclusion criteria are inadequately described. What chronic diseases are important to exclude and why? How will you identify patients with 3mm thick skin preoperatively ie. when you recruit them as this will surely be an intraoperative finding? So, will you exclude them latently or keep them and analyse on an ITT basis? Answer: We truly should have more clearly described which chronic diseases must be excluded. We have added the detailed contents in the exclusion criteria section as follows: "chronic diseases that could affect normal wound healing, such as diabetes, chronic kidney disease, malignant neoplasms, and severe malnutrition". Skin thickness was defined as an exclusion criterion in the original manuscript because thin skin is inconvenient for performing subcutaneous suturing. However, the thickness of the skin in the chest generally meets the operational requirements. Thus, we have removed this exclusion criterion in the revised version. 4. I feel the authors should rethink their split-scar (within subject) randomisation -there is a wealth of data on this topic and its limitations in the absence of a cross-over or repeated measures design. The split-scar model may cause serious issues: a) There will be difficulty in assessing and interpreting outcomes (ie. which bit of the half of the scar does the patient/assessor look at to decide the outcomes? The middle of the half? The edge? The junction? All of it? Does the VSS/POSAS allow this approach i.e is it validated in a split-scar model? What if your new suture reduces tension on the other half of the incision, confounding the effect of the BID? Also, these are small incisions and is it practical to halve the wound for different suturing? And both halves will received a running intradermal (final, to approximate epidermis) suture so there will be a common factor, making the groups related rather than different...Moreover, a split-scar model would cause major issues with the statistical analysis and external validity; the observations would no longer be independent (as they're from the same wound, same person, etc) and so more complex modeling is required to adjust for this related data, meaning the sample must be much larger if you're seeking to find a prescirbed difference (certainly far more than the 20 planned). Overall, I think the authors should consider randomising patients, rather than using a split-scar model and tackle this first in a feasibility trial. Answer: Thank you very much for the suggestions. As you said, there is a substantial amount of relevant information regarding the split-scar model. Indeed, there are certain flaws in its operation and the evaluation of results. Since one wound is divided into two and sutured with different methods, there will be mutual interference in the junction. Therefore, we decided to use the midpoint of each intervention for evaluation. This place is a certain distance away from the junction; thus, using this area can avoid the bias caused by tension changes and thoroughly reflect the effect of stitching. Indeed, a small incision was not conducive to halve the wound for different forms of suturing, but in the pretest, we found that this operation can be achieved in wounds more than 3 cm. Scar assessment tools (POSAS, etc.) can be applied to the evaluation of this split-scar model, which has been proven to be reliable and feasible in many articles. [1] [2] [3] [4] [5] In addition, this model allows observers to compare different interventions in the same visual field, which is more conducive to the assessment of results. At the end of the surgery, the epidermis is approximated in the same method by a running intradermal suture. This approach will help us to eliminate the bias caused by the different epidermis suturing methods and make the comparison of subcutaneous suture techniques more visible and credible. Although the split-scar model has some disadvantages as you mentioned, its advantages cannot be ignored. The model that is used to compare different interventions within the same wound will help to minimise confounders caused by genetics and reduce the sample size needed to detect a significant difference. Based on this model, the study will be a self-paired trial, and the results will be significant. Overall, we think that use of the split-scar model in the feasibility trial is more valuable to a future full RCT. 5. The exact statistical test used to analyse the data will depend on the type, releatedness and distribution of the data, which in turn depends on the outcome measure that you use. There's no need to stipulate this in such detail yet or the software used. Answer: Thank you very much for the suggestions. In line with the recommendations for good practice in the analysis of feasibility studies, the analysis will be descriptive, and no statistical comparisons of the outcomes will be conducted. Descriptive statistics will be calculated for the outcomes. We have simplified the "Statistical analyses" section in the revised version. (page 6) 6. The authors must discuss if patients will be blinded and how. This would then imply whether outcome measures were blind. Answer: Thanks for your suggestion. Because patients will assess the cosmetic outcomes of scars, they will be blinded to allocation. We have added the detailed contents in the blinding section as follows: "The patient knows only that two techniques will be applied and does not know whether these techniques are specific to the left side or right side." 7. The authors should record if/when skin is excised as clearly, when more skin is removed there will be more tension at the repair. This varaible could inform sensitivity analyses. Answer: According to the comments from the reviewer, we have added the detailed contents in the intervention section as follows: "Then, any skin contused during the operation is excised as cleanly as possible". Generally, the amount of skin excised is no more than 1 mm. However, the bias resulting from such a small amount of skin tension changes is negligible. 8. Scars take months-years to mature and a 3-month follow-up alone will not identify hypertrophic or keloid scars. Also, as scars mature, the PSOAS/VSS scores will change. The authors cite Quinn et al's work to justify their approach but Quinn's trial considered 77 traumatic lacerations closed with glue vs sutures and the agreement between 3 month and 1 year POSAS scar scores was not good (kappa=0.7; 95% CI 0.5 -0.9 which implies moderate agreement, with a confidence interval from no agreement to 0.9, strong). Quinn's data is not transferable to this trial and doesn't imply 3-monthyl followup is sufficient. I recommend the authors better justify theic choice of 3 month only follow-up (provide better date) or consider extending their surveillance period to capture all adverse outcomes (which is expected in trials these-days). Answer: We agree with the point that a 3-month follow-up is short and may limit our results. Quinn et al.'s work had some limitations, but it did provide some hints. In similar experiments,[6-9] differences in cosmetic outcomes were already detected 3 months after interventions. At 3 months after an intervention, a subcutaneous absorbable suture (VICRYL Plus, Polyglactin 910) is almost completely absorbed; then, the effect of reduced tension will gradually disappear, and differences in surgical interventions will tend to diminish. Therefore, we decided to use 3 months as a follow-up point. For observing changes in the appearance of scars, we will certainly continue the follow-up to 6 months and 1 year when the scars have matured. (6): p. 691-5. 9. In the blinding paragraph there is a typo for POSAS. Answer: Thanks for the suggestions. The sentence in the original manuscript is "The OSAS will be completed by 2 blinded observers for validity." The OSAS (the observer scar assessment scale) is a part of the POSAS and needs observers to complete; thus, this text is perhaps not a typo. 10. How will the wounds be dressed afterwards? Will sticky strips (suture strips, steri-strips, etc) be applied? What will be post-op wound care regime entail? Answer: According to the comments, we have added detailed contents regarding postoperative wound care in the "Study interventions" section. After the surgery, the adhesive strips (Steris trips, 3M Healthcare) and surgical dressing will be applied to the wound. Postoperative suggestions and medications will be identical for both sides of the wound. A nurse will disinfect the wound with iodophor and replace the adhesive strips and surgical dressing once every 3 days for 9 days. 11. Who will deliver/facilitate the outcomes measures? Will the authors be there or will an independent professional administer the questionnaires? Answer: Thank you very much for the suggestions. We have added the detailed contents regarding who will facilitate the outcome measures in the "Follow-up" section as follows: "Wound data immediately postoperatively and complications during follow-up will be measured or recorded by dedicated personnel. At all follow-up points, patients and two blinded observers will be asked to complete the scales for the cosmetic outcomes of scars administered by a professional questionnaire administrator." In detail, Zonghui Liu will measure wound data immediately postoperatively; Xiangyu Liu will record data during the follow-up period; Rui Wang, as the professional questionnaire administrator, will collect data at the end of the follow-up. At the end of the trial, Xiangyu Liu and Rui Wang will summarise all data and input electronic data capture (EDC, ResMan online, http://www.medresman.org/uc/index.aspx). Analysis: 1. Your sample size calculation is based on a "paired t-test" although this may need to change if you move to a between-subject design. Also, why was a difference of 5 points chosen? Is this a known minimally clinically important difference? This should be justified: I imagine this data is based on between subject measurements and so this may not be valid in a split-scar model. Also, a SD of 7 needs explaining. If this were designed as a feasibility RCT as I suggest, then a fixed sample size of 20 is acceptable (Lancaster et al. Design and analysis of pilot studies: recommendations for good practice. Journal of evaluation in clinical practice. 2004), but this is not based in statistical power. Answer: Thank you very much for the suggestions. As this is a feasibility study, formal power calculations were not carried out. Using the split-scar model could reduce the sample size. Therefore, we used paired t-test to calculate the sample size. The difference of 5 and the SD of 7 were set to with reference to a similar clinical trial design. [10, 11] We think that the sample size will be adequate to estimate critical parameters, although no formal power calculations have been undertaken. Answer: Thank you very much for the suggestion. The analysis will be undertaken on an intention-totreat basis, analysing participants in the group to which they have been randomised and will comprise complete cases only. The trial should be registered on a trial database which I advise the authors to begin (eg. clinicaltrials.gov). It is crucial that plastic surgeons undertake more trials and so I congratulate you all on your plans and design thus far. I sincerely hope that my comments are helpful to you in revising this manuscript, such that it is then acceptable for publication and I wish you the very best in doing so. I'd be happy to review a revision and provide any further explanations/information as needed. Answer: This trial has been registered with the Chinese Clinical Trial Registry (http://www.chictr.org.cn) with identifier ChiCTR-INR-17013335. Thank you again for your valuable advice. We will do our best to undertake this clinical trial.
VERSION 2 -REVIEW

REVIEWER
Ryckie Wade The University of Leeds Leeds Teaching Hospitals NHS Trust REVIEW RETURNED 24-Jul-2018
GENERAL COMMENTS
Thank you for the opportunity to review your revised work. As before, I congratulate your plans for this surgical trial which will generate much-needed outcome data on suturing techniques and scar outcomes. I sincerely hope my comments are helpful to you in making this planned feasibility trial as good as possible, prior to publication.
Something which escaped my notice 1st time is the use of the POSAS and VSS in children. You're recruiting 6-18 year olds -are there equivalent paediatric scales? I'm don't think these are validated in children? I'm quite sure a 7 year old wouldn't understand pliability although I accept their guardian may be able to provide this data as a proxy, but then why not just have an independent assessor? I'm sure you plan to discuss/describe these data but perhaps it may be worth protocolising this aspect?
Specific points (original pagination) are highlighted in the attached: p1, line45 -remove claims of being the first p3, line10 -does this mean that the trial is already recruiting? p3, line33 -what is the approximate length of the skin incision? p4 line47 -typo p5, line7 -what are "spitting sutures"?
I'm sorry, but my main concern/confusion is still around the plan for a "split scar" design. Firstly, are you harvesting grafts from both sides of the patient (ie. harvesting both right and left costal cartilage graft), or operating on just one side of the chest wall and dividing that single wound in half? Either way, within-subject randomisation is fraught with problems which I advise against. If within-subject randomisation is used, then two remote incisions are preferable to remove "carryover effect(s)". If only one single incision is used to harvest your grafts, I recommend a between-subject randomisation design because each suturing technique on one incision will effect each-other and this cannot be ameliorated by a washout period. Therefore, your outcome data for a split-scar trial for BIS vs. WE-MBVMS will be dependent/confounded, so identifying subtle differences in scar outcome(s) will be difficult. You cite two trials which use split-scar models, but both are underpowered for the outcomes of interest, use scales to measure outcomes which don't permit split-scar designs and failed to show any differences. I'm concerned that by replicating their methods, you may have the same troubles. Contrary to your statement, within-subject randomisation introduces new confounding (the association between each suture technique and the outcome) which must be adjusted post-hoc. I've recommended that the BMJ obtain a 2nd statistical review in case I'm missing something / mistaken Also, there's no need to power feasibility trials -you are not seeking to show a preset difference. Most pilot/feasibility trials have n~30 which is supported by the literature (Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. Journal of evaluation in clinical practice. 2004 May 1;10(2):307-12.)
VERSION 2 -AUTHOR RESPONSE
Reviewer #3: Thank you for the opportunity to review your revised work. As before, I congratulate your plans for this surgical trial which will generate much-needed outcome data on suturing techniques and scar outcomes. I sincerely hope my comments are helpful to you in making this planned feasibility trial as good as possible, prior to publication.
Something which escaped my notice 1st time is the use of the POSAS and VSS in children. You're recruiting 6-18 year olds -are there equivalent paediatric scales? I'm don't think these are validated in children? I'm quite sure a 7 year old wouldn't understand pliability although I accept their guardian may be able to provide this data as a proxy, but then why not just have an independent assessor? I'm sure you plan to discuss/describe these data but perhaps it may be worth protocolising this aspect? 
GENERAL COMMENTS
Thank you for inviting me to review your revised protocol. I wish you the very best of luck in this much-needed study and sincerely look forward to reading the output.
